RNTX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Rein Therapeutics Inc | Needs refresh | Last updated: 2026-03-29T08:34:16Z

TickerRNTX

Market Cap35.0M

Cash RunwayRunway < 6 months

Next Catalyst2027-02

Public Research Snapshot

Rein Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Selinexor 60 mg in Myelofibrosis | Moderate Thrombocytopenia | Mild Thrombocytopenia (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Selinexor 60 mg	Myelofibrosis \| Moderate Thrombocytopenia \| Mild Thrombocytopenia	n/a	Phase 2	Public pipeline row
DISC-3405	Polycythemia Vera (PV)	n/a	Phase 2	Public pipeline row
ReIn-Hand	Stroke	n/a	Na	Public pipeline row
ReIn-Hand device assisted home-based practice	Stroke \| Hand Function	n/a	Na	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-02	DISC-3405	Low
		Clinical Trial Completion	2027-06	Selinexor 60 mg	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03986216	Na	COMPLETED	3	2021-03-18
NCT04077073	Na	COMPLETED	54	2024-09-27
NCT06985147	Phase 2	RECRUITING	60	2027-02
NCT05980806	Phase 2	RECRUITING	58	2027-06

Scientific Context

asset_name | DISC-3405
catalyst_date_estimated | 2027-02
catalyst_type | Clinical Trial Completion
clinical_stage | Phase 2
clinical_stage | Phase 2

Want the full RNTX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.